重庆医学2011，Vol.40Issue(25)：2523-2524,2526,3.DOI:10.3969/j.issn.1671-8348.2011.25.011
两个化疗方案治疗晚期非小细胞肺癌疗效观察
Efficacy comparison of two second-line chemotherapy to patients with advanced non-small-cell lung cancer
刘馨 1顾立学1
作者信息
- 1. 辽宁医学院附属第一医院检验科,辽宁锦州,121001
- 折叠
摘要
Abstract
Objective To compare the efficacy and safety of domestic pemetrexed and docetaxel singly used in treatment of patients with advanced non-small-cell lung cancer(NSCLC) who previously failed with first-line chemotherapy. Methods 86 patients with stage-Ⅲ B or stage-Ⅳ NSCLC who couldn't bear or failed in previous first-line chemotherapy were assigned to two groups:28 patients received pemetrexed 500 mg/m2 and 58 patients received docetaxel 75 mg/m2. All eligible patients received 2 cycles chemotherapy at least, 31 d for each cycle. Results There were 2 cases of PR, 17 cases of SD, 9 cases of PD in P group,and the total response rate was 7.14％ ,and disease control rate was 67.86％. There were 6 cases of RR,35 cases of SD,17 cases of PD,in P group and the total response rate was 10.34 ％ ,disease contal rate was 70.69 ％. The decrease rate of neutrophile granulocyte and hemoglobin,and occurence of rash in P group were significantly different from the corresponding itcm in P group (P＜0.05), the occurencs of other adverse reaction of the two groups were almost the same(P＞0.05). Conclusion Treatment with pemetrexed and docetaxel results in clinically equivalent efficacy in treatment of patients with advanced non small cell lung cancer(NSCLC)who previously failed with first-line chemotherapy. Both of the two treatments are safe and effective.关键词
培美曲塞二钠/多西他赛/非小细胞肺癌/化疗Key words
Pemetrexed/ Docetaxel/ Non-small-cell lung cancer/ Chemotherapy引用本文复制引用
刘馨,顾立学..两个化疗方案治疗晚期非小细胞肺癌疗效观察[J].重庆医学,2011,40(25):2523-2524,2526,3.
